The post says the effect is most likely during escalation or at higher maintenance amounts, concentrated in the first two to four weeks, and describes it as dose-dependent and often subsiding as the body adapts to the medication
91% achieved 15% reduction at highest dose
In addition to GLP-1/GIP/GCG receptors tri-agonists, there are also triagonists targeting Xenopus GLP-1/GCG/Cholecystokinin-2 (CCK2) receptors [107], GLP-1/GCG/ neuropeptide Y 2 receptors [108], and GLP-1R, neuropeptide Y1, and neuropeptide Y2 receptors [109]
EX, Exenatide EX-LAR, Long-acting release formulation of exenatide
The medication travels through your blood to reach receptors throughout your body
Understanding the available pathways helps inform decisions about whether and how to proceed